NCT05841277View on ClinicalTrials.gov

A Study of LY3819469 in Participants With Impaired and Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions
Renal InsufficiencyHealthy
Interventions
DRUG

LY3819469

Administered SC.

Trial Locations (4)

32808

Omega Research Consultants, Orlando

33016

Floridian Clinical Research, Miami

33417

Advanced Pharma CR, LLC, Miami

55114

Nucleus Networks, Saint Paul

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY